Here are the S-3 shelf registrations from Ernexa Therapeutics Inc. (ERNA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow ERNA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ERNA filings page.
Ernexa Therapeutics amended its shelf registration to permit up to $50,000,000 of securities and added an ATM sales agreement to sell up to $9,248,276 of common stock under the Sales Agreement with Brookline Capital Markets. The prospectus supplement describes an at-the-market program and notes prior financing: the Company completed a public offering on February 10, 2026 raising net proceeds of approximately $9.5 million and issued warrants, of which 21,000,000 Warrants from that offering remained outstanding as of March 20, 2026. The filing discloses Nasdaq noncompliance: on March 18, 2026 Nasdaq notified the Company that its common stock failed to maintain the $1.00 minimum bid price for 30 consecutive business days; the Company intends to request a hearing before the Nasdaq Hearing Panel to seek relief after a prior 1-for-15 reverse stock split.
Ernexa Therapeutics Inc. filed a shelf registration to offer up to $50,000,000 of securities and a sales agreement prospectus supplement establishing an ATM program to sell up to $9,248,276 of common stock through Brookline Capital Markets. The prospectus notes 29,154,431 shares outstanding as of March 12, 2026 and a public float of $27,744,830.12.
The company describes its lead preclinical iMSC candidate ERNA-101, recent pre-IND FDA alignment, a completed February 10, 2026 public offering that generated net proceeds of approximately $9.5 million, and Nasdaq compliance matters tied to the $1.00 minimum bid rule and a recent reverse stock split.